Head-to-head · Cost-Efficiency Index
Teleios Health vs AlyveRx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Teleios Health
Shoppers comfortable calling or messaging before committing, since public pricing detail is minimal.
Visit Teleios HealthAlyveRx
Shoppers who specifically want a needle-free sublingual GLP-1 option alongside standard injections on the same platform.
Visit AlyveRxThe verdict
Teleios Health takes it, leading the Cost-Efficiency Index 65 to 64. Teleios Health markets itself as a physician-led GLP-1 telehealth provider offering both compounded semaglutide and tirzepatide. AlyveRx still earns a C — Shoppers who specifically want a needle-free sublingual GLP-1 option alongside standard injections on the same platform.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Teleios Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Teleios Health | AlyveRx |
|---|---|---|
| Cost-Efficiency Index | 65/100 | 64/100 |
| Semaglutide / mo | $99/mo (all doses, compounded) | $183/mo (starting dose, compounded) |
| Tirzepatide / mo | Not disclosed | $283/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $1,188 | $2,196 |
| Tirzepatide / yr (modeled) | — | $3,396 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank here | #170 | #173 |
Teleios Health
65/100Where the value is
- Advertises a low $99/mo headline starting price, undercutting most compounded-GLP-1 competitors on paper
- Explicitly brands itself as 'physician-led,' setting an expectation of clinician oversight
- Discloses the standard compounded-medication FDA disclaimer up front rather than burying it
The tradeoffs
- No dose amount, drug, or inclusion breakdown is published for the $99/mo figure
- No visit fee, membership fee, or shipping fee disclosure could be found anywhere on the site
AlyveRx
64/100Where the value is
- Offers a genuinely needle-free sublingual delivery option (PermeAct) for both semaglutide and tirzepatide, not just injections
- Also carries brand-name Ozempic, Wegovy, and Mounjaro for patients who want an FDA-approved product
- All four price points (injection and drops, both drugs) are published upfront on the homepage before intake
The tradeoffs
- The dataset's previous $249/mo tirzepatide figure is the SUBLINGUAL DROPS price, not the standard injection ($283/mo) — confirm which form a quoted price refers to
- Sublingual PermeAct absorption relies on the company's own proprietary technology claims and is not FDA-reviewed for weight-loss efficacy
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.